Disease Spotlight: Prostate Cancer

For patients who received radiotherapy for localized prostate cancer, total intraprostatic tumor volume derived from AI segmentation had a 10 percent higher AUC for predicting seven-year metastases in comparison to a risk model from the National Comprehensive Cancer Network (NCCN).

For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.

Earlier detection of PSMA-avid lesions in post-radiotherapy patients with increases in PSA levels < 2 ng/ml above nadir were reportedly associated with a significantly lower incidence of distant metastases and lower overall mortality rates.

When employing a PI-RADS > 4 cutoff, researchers found that the mdprostate software provided an 85.5 percent sensitivity rate for diagnosing clinically significant prostate cancer on mpMRI.

In a recent interview, Lisa F. Newcomb, Ph.D., discussed the merits of active surveillance for low-risk prostate cancer (PCa) and key findings from multicenter research involving over 2,100 men with localized PCa.

PSMA PET/CT revealed progressive PCa in 31 percent of patients who demonstrated greater than a 50 percent decline in PSA level after treatment with either an androgen receptor-targeted agent or chemotherapy.

Omitting biopsy procedures in men with PSA levels > 3 ng/ml and negative MRI findings for prostate cancer (PCa) was associated with significantly lower risks of diagnosing clinically insignificant PCa in comparison to the use of systematic biopsy, according to an approximately four-year study of over 13,000 men who had prostate cancer screening.

Catch up on the most-well viewed radiology content in September 2024.

Catch up on the most-well viewed prostate imaging content in September 2024.

A new meta-analysis found that PSMA PET/CT offers a 12 percent higher positivity rate for detecting biochemical recurrence of PCa and a 19 percent higher positivity rate for identifying lymph node metastasis in comparison to mpMRI.

Catch up on the top radiology content of the past week.

The use of 177Lu-PSMA-617 was associated with a significantly longer radiographic progression-free survival and a 12 percent lower rate of grade 3 or higher adverse events in comparison to a change of ARPI therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

For patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastasis, the combination of enzalutamide and Ra223 led to a median overall survival rate of 42.3 months in contrast to 35 months for enzalutamide alone, according to research presented at the 2024 European Society for Medical Oncology Congress (ESMO) in Spain.

The PSMA-targeted modality 177Lu-PNT2002 improved radiographic progression-free survival by 29 percent in patients with mCRPC in comparison to ARPI therapy, according to new phase 3 trial data presented at the ESMO Congress in Spain.

For clinically significant prostate cancer, multiparametric MRI (mpMRI) has a pooled sensitivity rate of 88 percent in biopsy-naïve men, according to a new 16-study meta-analysis.

Currently in phase III trials, the 64Cu-SAR-bisPSMA PET agent reportedly offers a longer half-life and higher tumor uptake than other radiopharmaceuticals for prostate cancer imaging.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Prostate biopsy reclassification was 2.3 times more likely with PI-RADS > 4 lesions in patients in comparison to those with PI-RADS 1-3 lesion assessments, according to new MRI research involving nearly 1,500 men with low-risk and favorable intermediate risk for prostate cancer.

New research revealed an 86 percent AUC for deep learning detection of clinically significant prostate cancer in comparison to 84 percent for four abdominal radiologists with at least 10 years of experience.

Emerging research revealed a median progression-free survival of 16.4 months and a 29-month mean freedom from a new line of systemic therapy for the use of PSMA PET/CT guided, metastasis-targeted radiotherapy for patients with oligometastatic castration-resistant PCa.

Catch up on the top AI-related news and research in radiology over the past month.

Catch up on the most-well viewed radiology content in July 2024.

Catch up on the most-well viewed prostate cancer imaging content in July 2024.

A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.

In comparison to systematic biopsy, researchers found that mpMRI-targeted biopsy had a nine percent higher detection rate for cribriform and intraductal prostate cancer subtypes that are associated with adverse outcomes.

Catch up on the top radiology content of the past week.

The MIM Software HDR Prostate reportedly enables clinicians to utilize preoperative MRI guidance and live ultrasound imaging to enhance tumor visualization during high dose-rate (HDR) brachytherapy treatments for prostate cancer.

For men with prostate cancer, new research demonstrates that 18F-PSMA-1007 PET/CT is 17 percent more accurate than mpMRI at identifying the final pathological tumor stage and 12 percent more accurate in detecting extracapsular extension.

In preliminary research, the targeted alpharadiotherapy agent 225Ac-FL-020 has demonstrated superior antitumor activity in xenograft models and a favorable safety profile.